Sara Niego, MD
Psychiatry · Hartford, CTNPI 1730193814
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 1,329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,329 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Lundbeck LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $11K from 33 others
What the payments were for
- Food & beverage$24,73498%
- Education$4312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,165 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 24 | $93,447 |
| TrintellixVortioxetine Hydrobromide | 42 | $57,894 |
| VraylarCariprazine Hcl | 20 | $52,105 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $27,660 |
| Lurasidone Hcl | 23 | $11,543 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $11,030 |
| QuviviqDaridorexant Hcl | 15 | $8,211 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $7,692 |
| Duloxetine Hcl | 80 | $6,028 |
| Loreev XrLorazepam | 13 | $5,857 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $5,382 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 96 | $5,112 |
| Aripiprazole | 38 | $4,226 |
| Bupropion XlBupropion Hcl | 117 | $4,151 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 78 | $2,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,134 | $93,44724 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,946 | $65,58556 claims |
| AbbVieVraylar | $3,768 | $52,10520 claims |
| Alkermes, Inc.Lybalvi | $1,241 | $27,66016 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $182 | $8,21115 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $226 | $6,895115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Hartford
- Steven KatzHartford$18K
- Sergio MejiaHartford$6K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.